Lilly is betting that dulaglutide will stand out

Source: Ding Xiangyuan 2014-06-17 if Lilly launched the listing of dulaglutide, it will not be the first company to enter the GLP-1 diabetes treatment field, but Lilly believes that its drug data can stand out from competitors, and claims to occupy billions of dollars in the market Lilly has developed a 9-Step, 3-phase experimental scheme for the most likely competing product of dulaglutide, and the drug performance is not bad The once-a-week drug has so far beat AstraZeneca's Byetta, Merck's januvia and metformin in controlling blood sugar in type 2 diabetes At the meeting of the American Diabetes Association held on June 15, Lilly released its latest results, proving that dulaglutide is not inferior to the heavy bomb Victoza of Nord and Nord, which is the benchmark of GLP-1 therapeutic drugs, with a sales volume of 2 billion US dollars a year Lilly said it was the first time in a phase 3 trial that it had shown that its weekly GLP-1 drug had the same effect as its daily dose, which included the recently approved tanzeum from GlaxoSmithKline As regulators have combed five late stage studies in dulaglutide, Lilly's purpose of studying Victoza is not to deal with regulators, but to analyze the potential of drugs for the market Novo Nordisk currently holds about two-thirds of the GLP-1 market, with a total market value of about $3 billion, which analysts say could grow to $5 billion in the next few years Dulaglutide, with its easy-to-use syringes and weekly dosing regimen, will be Victoza's biggest threat, with sales estimated at up to $2 billion But when it comes to market competition, the issue of weight loss may not be conducive to Lilly's competition In the study of Victoza on dulaglutide, the weight loss of patients who used Novo Nordisk was significantly greater than that of patients who used Lilly drugs, about 8 pounds to 6.4 pounds, which was statistically significant The reason for this difference is unclear, because both groups in the study showed similar treatment dependence and gastrointestinal tolerance Nevertheless, the company points out that clinical effects are just as important as weight loss, and that dulaglutide is enough to reach the secondary end point Novo Nordisk is developing Victoza's special formula for weight loss, taking the opportunity to highlight its outstanding performance In a statement, the company said Lilly's achievements "have strengthened the effectiveness of Victoza in all clinical trials." If approved, Lilly's dulaglutide will be sold under the trade name of trulicity Source address: http://www.finebiotech.com/story/lily-bets-its-diabetes-drug-scheduled-can-dominate-crowded-class/2014-06-14